Germany’s contract development and manufacturing firm ProBioGen AG and Indonesian state-owned vaccines maker Bio Farma have signed an agreement for the development of a biosimilar trastuzumab, Swiss drug major Roche’s (ROG: SIX) blockbuster cancer drug Herceptin, for cancer treatment.
The goal of the cooperation is the supply of the Indonesian patients with cost-effective high quality biopharmaceuticals. Under the terms of the agreement ProBioGen will develop a highly efficient manufacturing process based on a specifically designed recombinant CHO-cell line, conduct engineering runs and the industrial scale-up.
Plan for local market production
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze